for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alligator Bioscience AB

ATORX.ST

Latest Trade

12.44SEK

Change

0.44(+3.67%)

Volume

43,663

Today's Range

12.22

 - 

12.50

52 Week Range

10.60

 - 

28.45

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
12.00
Open
12.50
Volume
43,663
3M AVG Volume
7.52
Today's High
12.50
Today's Low
12.22
52 Week High
28.45
52 Week Low
10.60
Shares Out (MIL)
71.39
Market Cap (MIL)
856.66
Forward P/E
-4.13
Dividend (Yield %)
--

Next Event

Q3 2019 Alligator Bioscience AB Earnings Release

Latest Developments

More

Alligator Bioscience April-June Operating Loss At SEK 50.5 Mln

Alligator Bioscience Q4 Net Sales Fall To SEK 25.6 Million

Alligator Bioscience Will Receive $3.5 Mln Under Agreement With Abclon

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Alligator Bioscience AB

Alligator Bioscience AB is a Sweden-based company that is engaged in development of immunotherapies for the treatment of cancer. The Company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In the discovery of those drugs, the Company uses its technology platforms ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a library containing human antibodies. FIND (which stands for Fragment Induced Diversity) is an antibody optimization technology. In its pipeline, the Company has thee projects: ADC-1013 (antibody), ATOR-1015 (bispecific immune activating antibody) and ATOR-1016 (bispecific agonistic antibody), which are in research/preclinical stage.

Industry

Biotechnology & Drugs

Contact Info

Scheelevagen 2 Byggnad 401

+46.46.2864280

https://alligatorbioscience.se/

Executive Leadership

Peter Arthur Benson

Chairman of the Board

Per Norlen

Chief Executive Officer, Chief Medical Officer

Per-Olof Schrewelius

Chief Financial Officer

Peter Ellmark

Vice President Discovery

Christina Furebring

Vice President Research and Development

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2016

0.1K

2017

0.1K

2018

0.0K

2019(E)

0.0K
EPS (SEK)

2016

-0.800

2017

-0.890

2018

-2.100

2019(E)

-2.908
Price To Earnings (TTM)
--
Price To Sales (TTM)
33.12
Price To Book (MRQ)
2.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
5.15
LT Debt To Equity (MRQ)
3.66
Return on Investment (TTM)
-35.37
Return on Equity (TTM)
-33.25

Latest News

Latest News

BRIEF-Alligator Bioscience Q1 Operating Loss Widens To SEK 44.0 Million

* Q1 OPERATING LOSS SEK 44.0 MILLION VERSUS LOSS SEK 19.1 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Alligator Bioscience AB Oct-Dec Net Sales, SEK 51.3 Million

* OCT-DEC OPERATING RESULT, SEK 10.7 MILLION (-22.1) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Alligator Bioscience Contracts Theradex Oncology As Clinical CRO

* ALLIGATOR BIOSCIENCE CONTRACTS THERADEX ONCOLOGY AS CLINICAL CRO FOR THE UPCOMING ATOR-1015 PHASE I STUDY

BRIEF-Alligator Bioscience To Receive Milestone Payment From Janssen

* ALLIGATOR BIOSCIENCE TO RECEIVE USD 6 MILLION MILESTONE PAYMENT FROM JANSSEN COUPLED TO THE DECISION TO INITIATE COMBINATION TRIAL WITH ADC-1013

BRIEF-Alligator Bioscience appoints Charlotte A Russell as Chief Medical Officer​

* ALLIGATOR BIOSCIENCE AB - APPOINTMENT OF CHARLOTTE A RUSSELL AS CHIEF MEDICAL OFFICER

BRIEF-Alligator Bioscience ‍Q3 operating loss widens to SEK 24.5 mln​

* Q3 OPERATING LOSS, SEK 24.5 MILLION (LOSS: 9.1) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Aptevo Therapeutics and Alligator Bioscience announced further details of collaboration on ALG.APV-527​

* Aptevo Therapeutics Inc - co, Alligator Bioscience announced further details of companies' collaboration on ALG.APV-527 Source text for Eikon: Further company coverage:

BRIEF-Alligator Bioscience signs collaboration agreement for 4-1BB

* ALLIGATOR BIOSCIENCE SIGNS IMMUNOTHERAPY RESEARCH COLLABORATION AGREEMENT FOR 4-1BB

BRIEF-Alligator Bioscience Q2 operating loss lowers to SEK 29.5 mln

* Q2 NET SALES SEK 1.3 MILLION VERSUS SEK 3.8 MILLION YEAR AGO

BRIEF-Aptevo and Alligator Bioscience start IND-enabling development activities immunotherapy drug

* Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 Source text for Eikon: Further company coverage:

BRIEF-Alligator Bioscience expands collaboration with Stanford University

* EXPANDS IMMUNO-ONCOLOGY COLLABORATION WITH STANFORD UNIVERSITY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Aptevo Therapeutics and Alligator Bioscience to co-develop novel bispecific antibody

* APTEVO THERAPEUTICS AND ALLIGATOR BIOSCIENCE ANNOUNCE PLANS TO CO-DEVELOP NOVEL BISPECIFIC ANTIBODY FOR TUMOR-DIRECTED IMMUNOTHERAPY

BRIEF-Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

* Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

BRIEF-Alligator Bioscience advances ATOR-1017 into pre-clinical development​

* ALLIGATOR BIOSCIENCE HAS ADVANCED ANOTHER WHOLLY-OWNED CHECKPOINT MODULATOR PROGRAM, ATOR-1017, INTO PRE-CLINICAL DEVELOPMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Alligator Bioscience Q1 operating result swings to loss SEK 19.1 million

* Q1 NET SALES SEK 2.5 MILLION VERSUS SEK 43.4 MILLION YEAR AGO

BRIEF-Alligator: completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013

* Announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013

BRIEF-Alligator Bioscience Q4 operating loss narrows to SEK 22.1 mln

* Q4 net sales 6.4 million Swedish crowns ($725,000) versus 0.5 million crowns year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up